While the primary focus of RNA Disruption Assay (RDA) continues to be breast cancer chemotherapy management, it is rapidly evolving into a platform technology that will be utilized in the management of treatments across multiple cancers. RDA is now being employed in clinical trials for […]
Rna Diagnostics announces the study, Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy, recently published in Breast Cancer Research and Treatment.
Rna Diagnostics is a Canadian cancer diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RDA, evaluates early in a woman’s […]
RNA Diagnostics, a Sudbury-based medical diagnostic company, has successfully closed an additional round of angel investment with support of the NORCAT Innovation Mill Angel group.
RNA Diagnostics, with their patented RNA Disruption Assay™ (RDA™), enables clinicians to identify patients who are not responding to chemotherapy early […]
Interactive cost benefit model shows use of RDA in the neoadjuvant setting cost effective for German payers.
Breast cancer stakeholders attended the 34th Annual Meeting of the German Society for Senology conference featuring up-to-date breast cancer diagnostics and therapies. RDA was represented there via Assessment in […]
Rna Diagnostics aims for $150M in revenues by 2019
If all goes according to plan, a Toronto-based medical diagnostics company expects to create more than 50 jobs in Sudbury over the next five years.
Rna Diagnostics’ head office may be in Toronto, but the team of researchers […]
